Thank you for Subscribing to Life Science Review Weekly Brief
Jigar Raythatha, former Chief Executive Officer of Constellation Pharmaceuticals and former Jounce Chief Business Officer, has been appointed to the board of directors of Jounce Therapeutics.
FREMONT, CA: Jigar Raythatha, former Chief Executive Officer of Constellation Pharmaceuticals and Jounce Chief Business Officer, has been appointed to the board of directors of Jounce Therapeutics, Inc., a clinical-stage organization centered on the discovery and development of novel cancer immunotherapy's and predictive biomarkers.
"It's incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring over 20 years of biotechnology industry experience, but he also comes with a unique position as an early employee of the company at its inception," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Jigars leadership and business development expertise will enhance our board's diversified perspective. He was an integral part of creating the Jounce we know today, and we all look forward to collaborating with him once again."
"Over the course of the last several years, Jounce has established a strong position as a leader in novel immuno-oncology drug discovery, and I am thrilled to join the board at this time in the companys life cycle.
Jounces recent growth, pipeline diversification and partnership strategy are core to its track record as a leader in transforming the immuno-oncology landscape," said Jigar Raythatha. "I look forward to providing insights from my prior experience with the company, coupled with my perspective as a former chief executive officer in the biotechnology industry."
In addition to Mr. Raythathas's appointment, Jounce also stated that Cary Pfeffer, M.D., a partner at Third Rock Ventures, a founding board member, and former interim chief executive officer, will retire from the Jounce board, effective December 31, 2021. Dr. Pfeffer has been a member of Jounce's board of directors since its inception in 2013 and served as its chair from 2014 to 2016.
"On behalf of the Jounce Board of Directors, I want to thank Cary for his years of dedication to Jounces science, team and mission," said Perry Karsen, chair of the Board of Jounce Therapeutics. "Cary's initial vision, his continuous guidance, and his unwavering support were invaluable to the creation and development of Jounces Translational Science Platform, helping us furthers our goal of matching the right immunotherapy to the right patients for meaningful and long-lasting therapeutic benefit."